Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vildagliptin + glimepiride
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Vildagliptin + glimepiride is an oral combination of two antidiabetic agents used in the management of type 2 diabetes mellitus. **Vildagliptin** is a potent, selective inhibitor of dipeptidyl peptidase-4 (DPP-4), which increases the availability of endogenous incretin hormones, notably *glucagon-like peptide-1 (GLP-1)* and *glucose-dependent insulinotropic polypeptide (GIP)*, resulting in enhanced glucose-dependent insulin secretion and suppression of inappropriate glucagon release. **Glimepiride** is a sulfonylurea that stimulates pancreatic beta cells to release insulin independently of blood glucose concentration. Used together, their complementary mechanisms target both fasting and postprandial glucose levels, improving glycemic control in patients not adequately controlled with metformin plus sulfonylurea dual therapy.
- Other names
- vildagliptin + glimepiride
02
Targets
KATP channel (ATP-sensitive potassium channel)DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on vildagliptin + glimepiride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vildagliptin + glimepiride.